Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues

Clinical Cancer Research

Volumn 17, Issue 11, 2011, Pages 3727-3732

  Rimsza, Lisa M ^a   Wright, George ^d   Schwartz, Mark ^b   Chan, Wing C ^e   Jaffe, Elaine S ^d   Gascoyne, Randy D ^h   Campo, Elias ⁱ   Rosenwald, Andreas ^j   Ott, German ^k   Cook, James R ^f   Tubbs, Raymond R ^g   Braziel, Rita M ^g   Delabie, Jan ^l   Miller, Tom P ^c   Staudt, Louis M ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b High ThroughPut Genomics   (Spain)

^c UNIVERSITY OF ARIZONA   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h BRITISH COLUMBIA CANCER AGENCY   (Canada)

ⁱ UNIVERSITY OF BARCELONA   (Spain)

^j UNIVERSITY OF WÜRZBURG   (Germany)

^k ROBERT BOSCH HOSPITAL   (Germany)

^l OSLO UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ACCURACY; ACTIVATED B CELL; ARTICLE; B LYMPHOCYTE; CANCER CLASSIFICATION; CELL OF ORIGIN CLASSIFICATION; CONTROLLED STUDY; FROZEN SECTION; GENE EXPRESSION PROFILING; GERMINAL CENTER B CELL; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; NUCLEASE PROTECTION ASSAY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

EID: 79957887434     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2573     Document Type: Article

References (21)

1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11. (Pubitemid 30082188)
2. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005;106:3183-90. (Pubitemid 41565917)
3. Iqbal J, Sanger WG, Horsman DE, Rosenwald A, Pickering DL, Dave S, et al. BCL2 translocation defines a subset of DLBCL with germinal center B-cell-like gene expression profiles and preferential expression of a set of genes. Blood 2003;102:884A.
4. Bea S, Colomo L, Lopez-Guillermo AL, Salaverria I, Puig X, Pinyol M, et al. Clinicopathologic significance and prognostic value of chromosomal imbalances in diffuse large B-Cell lymphomas. J Clin Oncol 2004;22:3498-506. (Pubitemid 41103656)
5. Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, Hottelet M, et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005;11:28-40. (Pubitemid 40075775)
6. Lenz G, Nagel I, Siebert R, Roschke AV, Sanger W, Wright GW, et al. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med 2007;204:633-43. (Pubitemid 46457085)
7. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 2008;105:13520-5.
8. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2003;100:9991-6. (Pubitemid 37087056)
9. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large Bcell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82. (Pubitemid 38029949)
10. Ott G, Ziepert M, Klapper W, Horn H, Szczepanowski M, Bernd HW, et al. Immunoblastic morphology but not the immunohistochemical GCB/non-GCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 2010;116:4916-25.
11. Choi WWL, Weisenburger DD, Greiner TC, Piris MA, BanhamAH, Jaye DL, et al. A new immunostain algorithm improves the classification of diffuse large B-cell lymphoma into prognostically significant subgroups. Mod Pathol 2008;21:250A.
12. Rimsza LM, LeBlanc ML, Unger JM, Miller TP, Grogan TM, Persky DO, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 2008;112:3425-33.
13. Roberts RA, Sabalos CM, LeBlanc ML, Martel RR, Frutiger YM, Unger JM, et al. Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large B-cell lymphoma. Lab Invest 2007;87:979-97. (Pubitemid 47429191)
14. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004;350:1828-37. (Pubitemid 38917249)
15. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-47. (Pubitemid 34651353)
16. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74. (Pubitemid 34101731)
17. Tome ME, Johnson DBF, Rimsza LM, Roberts RA, Grogan TM, Miller TP, et al. A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis. Blood 2005;106:3594-601. (Pubitemid 41609198)
18. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313-23.
19. Lossos IS, Czerwinski DK, Wechser MA, Levy R. Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies. Leukemia 2003;17:789-95. (Pubitemid 36519378)
20. Williams PM, Li R, Johnson NA, Wright G, Heath JD, Gascoyne RD. A novel method of amplification of FFPET-derivedRNAenables accurate disease classification with microarrays. J Mol Diagn 2010;5:680-6.
21. Dave SS, Fu K, WrightGW,LamLT, Kluin P, Boerma EJ, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006;354:2431-42. (Pubitemid 43855046)